<DOC>
	<DOCNO>NCT02877264</DOCNO>
	<brief_summary>This randomize , single-center , open-label , three-period , six-sequence , crossover , comparative study evaluate oral bioavailability single dos three vapendavir drug product formulation ( 264 mg free base tablet [ test drug ] , 264 mg free base oral suspension [ test drug ] , two 132 mg phosphate salt capsule [ reference drug ] ) healthy volunteer . The study design consist six dosing sequence . Each sequence comprise 3 period subject administer one three dose formulation first period . A subject receive different formulation subsequent period , subject receive formulation . The period separate approximate 7-day washout .</brief_summary>
	<brief_title>A Study Compare Oral Bioavailability Single Doses Three Vapendavir Drug Formulations Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>1 . Must healthy male female 19 60 year age ( inclusive ) time sign informed consent weigh â‰¥50 kg BMI 18 32.0 kg/m2 ( inclusive ) ; 2 . Capable give write informed consent ; 3 . Subject able understand comply protocol requirement , instruction restriction ; 4 . Healthy basis physical examination , medical history , VS , ECGs , clinical laboratory test ; 5 . Female subject postmenopausal least 2 year surgically sterile complete hysterectomy bilateral oophorectomy male subject , surgically sterile via vasectomy , must agree use double barrier method birth control , , condom plus spermicidal agent ( foam/gel/film/cream/suppository ) Study Day 0 30 day completion study . This include female subject use hormonal contraception ; 6 . Female subject must breastfeed pregnant . 1 . Positive result screen hepatitis B , hepatitis C , HIV ; 2 . No use tobacco product , well electronic cigarette , within 14 day Study Day 1 unwilling abstain study participation ; 3 . A medical history clinical evidence clinical condition may , opinion Investigator Medical Monitor , impact subject 's ability participate study , study result ; 4 . Current recent respiratory infection within 14 day screen ; 5 . Presence history significant allergy require treatment ; 6 . Clinically significant abnormality ECG ; 7 . Vital sign represent abnormal systolic blood pressure and/or abnormal diastolic blood pressure ; 8 . Safety laboratory abnormality screen Study Day 0 clinically significant ; 9 . Subject history drug abuse alcohol abuse past 2 year current evidence abuse addiction ; 10 . A positive urine drug screen test screen admission study facility ; 11 . A positive breathalyzer alcohol screen admission study facility ; 12 . A positive pregnancy test screen admission study facility ; 13 . Abstinence alcohol must employ 72 hour Study Day 1 throughout duration study participation ; 14 . Use chronic prescription medication within 90 day , exception hormonal contraceptive ( contraceptive device contain hormonal contraceptive ) take female subject within 14 day , overthecounter ( OTC ) medication , include vitamin , herbal , mineral supplement , within 7 day prior Study Day 1 throughout study participation ; 15 . Received investigational drug investigational vaccine within 30 day , use investigational medical device within 30 day prior Study Day 1 ; 16 . Any prior use vapendavir inclusion previous vapendavir investigational study ongoing participation vapendavir investigational study ; 17 . Donation loss whole blood within 60 day plasma within 14 day Study Day 1 anytime screen 30 day completion study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Vapendavir</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Biological Availability</keyword>
	<keyword>Volunteers</keyword>
</DOC>